

Evidence Supporting a Role for Constitutive Ghrelin Receptor Signaling in Fasting-Induced Hyperphagia in Male Mice

Q:1,2,3,4

Gimena Fernandez,¹ Agustina Cabral,¹ María F. Andreoli,² Alexandra Labarthe,³ Céline M'Kadmi,⁴ Jorge G. Ramos,² Jacky Marie,⁴ Jean-Alain Fehrentz,⁴ Jacques Epelbaum,^{3,5} Virginie Tolle,³ and Mario Perello¹

¹Laboratory of Neurophysiology of the Multidisciplinary Institute of Cell Biology (Argentine Research Council and Scientific Research Commission, Province of Buenos Aires, National University of La Plata), La Plata, Buenos Aires, Argentina; ²School of Biochemistry and Biological Sciences, National University of Litoral and Institute of Environmental Health, Santa Fe, Argentina; ³Centre de Psychiatrie et Neurosciences UMR_S894 INSERM Université Paris Descartes, Sorbonne Paris-Cité, 75014 Paris, France; ⁴Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-Université Montpellier-ENSCM, Faculté de Pharmacie, 34093 Montpellier, France; and ⁵MECADEV UMR 7179 Centre National de la Recherche Scientifique, Muséum National d'Histoire Naturelle France, 91800 Brunoy, France

Ghrelin is a potent orexigenic peptide hormone that acts through the growth hormone secretagogue receptor (GHSR), a G-protein-coupled receptor highly expressed in the hypothalamus. *In vitro* studies have shown that GHSR displays a high constitutive activity, whose physiological relevance is uncertain. As GHSR gene expression in the hypothalamus is known to increase in fasting conditions, we tested the hypothesis that constitutive GHSR activity at the hypothalamic level drives the fasting-induced hyperphagia. We found that refeed wild-type (WT) mice displayed a robust hyperphagia that continued for 5 days after refeeding and changed their food intake daily pattern. Fasted WT mice showed an increase in plasma ghrelin levels, as well as in GHSR expression levels and ghrelin binding sites in the hypothalamic arcuate nucleus. When fasting-refeeding responses were evaluated in ghrelin- or GHSR-deficient mice, only the latter displayed an ~15% smaller hyperphagia, compared with WT mice. Finally, fasting-induced hyperphagia of WT mice was significantly smaller in mice centrally treated with the GHSR inverse agonist K-(D-1-Nal)-FwLL-NH₂, compared with mice treated with vehicle, whereas it was unaffected in mice centrally treated with the GHSR antagonists D-Lys3-growth hormone-releasing peptide 6 or JMV2959. Taken together, genetic models and pharmacological results support the notion that constitutive GHSR activity modulates the magnitude of the compensatory hyperphagia triggered by fasting. Thus, the hypothalamic GHSR signaling system could affect the set point of daily food intake, independently of plasma ghrelin levels, in situations of negative energy balance. (*Endocrinology* 159: 1–15, 2018)

Ghrelin is a 28-residue octanoylated peptide predominantly secreted from endocrine cells of the stomach (1). Ghrelin is recognized as a highly potent orexigenic peptide hormone (2). In addition, ghrelin plays a variety of other physiological roles that include, but are not limited to, modulation of growth hormone secretion, blood glucose homeostasis, and stress

response, among others (2). In humans and rodents, plasma ghrelin levels rise before meals and then decrease postprandially (3, 4). Ghrelin acts via its unique receptor, the growth hormone secretagogue receptor (GHSR), which is a G-protein-coupled receptor (GPCR) highly expressed in the hypothalamus (5). GHSR is particularly enriched in neuropeptide Y (NPY) and agouti-related

ISSN Online 1945-7170

Copyright © 2018 Endocrine Society

Received 1 November 2017. Accepted 21 December 2017.

First Published Online ■■■ ■■■ 2017

Abbreviations: AgRP, agouti-related protein; ANOVA, analysis of variance; ARC, arcuate nucleus; DAB, diaminobenzidine; F-ghrelin, fluorescein-ghrelin(1–18); GHRP-6, growth hormone-releasing peptide 6; GHSR, growth hormone secretagogue receptor; GPCR, G-protein-coupled receptor; ICV, intracerebroventricular; IR, immunoreactive; KO, knockout; NPY, neuropeptide Y; POMC, proopiomelanocortin; SEM, standard error of the mean; WT, wild-type.

protein (AgRP) neurons of the hypothalamic arcuate nucleus (ARC), which are a key target of circulating ghrelin to increase food intake (6–9).

GHSR is recognized as a GPCR that displays an unusually high constitutive activity. Specifically, *in vitro* studies showed GHSR signals with ~50% of the maximum activity in the absence of ghrelin (10, 11). Notably, most studies concerning constitutive GHSR activity have focused on molecular aspects of this phenomenon, whereas the magnitude of its *in vivo* effects and physiological relevance are uncertain (12). To study the *in vivo* impact of constitutive GHSR activity, two studies in rodents have tested the effect of GHSR inverse agonists, which reduce constitutive activity. In the first one, *ad libitum*-fed rats chronically treated with central infusions of the GHSR inverse agonist [*d*-Arg1,*d*-Phe5,*d*-Trp7,9, Leu11]-substance P reduced their food intake and body weight (13). However, this analog of substance P also acts on other GPCRs, raising some concerns about its specificity for GHSR when used *in vivo* (14, 15). The other study used central administration of the GHSR inverse agonist K-(D-1-Nal)-FwLL-NH₂ and also found a decrease in food intake in *ad libitum*-fed rats (16). Genetic manipulations of the ghrelin system in rodents also suggest that constitutive GHSR activity may have *in vivo* implications. In particular, most studies using ghrelin knockout (KO) mouse models, fed with either regular chow or a high-fat diet, do not show substantial differences in terms of food intake or body weight, compared with wild-type (WT) mice (17). In contrast, some studies using GHSR-deficient mouse models fed with regular chow showed a subtle but substantial decrease in body weight, compared with WT mice, and such differences were enhanced when mice were either aged or fed with a high-fat diet from weaning (17). The fact that mice lacking GHSR exhibit more robust alterations in eating behaviors, compared with ghrelin KO mice, may be an indication that the latter retains high constitutive GHSR activity (17). In humans, a role for constitutive GHSR activity is suggested by a naturally occurring mutation (Ala204Glu) that selectively abolishes constitutive activity without altering ghrelin-evoked activity and leads to familial short stature (18). In addition, another study reported some mutations of GHSR that impact on its constitutive GHSR activity and also lead to short stature in humans (19). Altogether, these findings suggest that constitutive GHSR activity may play a role *in vivo*, independently of ghrelin action.

The ghrelin/GHSR system helps to cope against energy deficit conditions. Thus, the relevance of the GHSR signaling becomes more evident in situations such as fasting or caloric restriction, when the ghrelin/GHSR system is up-regulated and activates a number of

responses that contribute to maintain glycemia and drive food intake (20). Plasma ghrelin levels increase under fasting in both humans and rodents (21, 22). In addition, GHSR mRNA levels increase in the hypothalamus of fasted rodents (23–25), and the hypothalamic responsiveness to a GHSR agonist, measured by the induction of the marker of neuronal activation *c-Fos*, increases in fasted rats (26). Notably, central GHSR signaling seems to be more relevant during prolonged fasting, compared with short fasting periods, despite that similar plasma ghrelin levels are found in 24 or 48 hour fasted mice (24, 27). Under fasting conditions, ARC NPY/AgRP neurons are activated, and the ARC neurons that produce anorexigenic peptides derived of the proopiomelanocortin (POMC) precursor are inhibited (28–30). The upregulation of NPY signaling is one of the key players known to drive the compensatory hyperphagia that fasted animals display when they have access to food (9, 31). Thus, it can be hypothesized that constitutive GHSR activity at the hypothalamic level modulates the compensatory hyperphagia that follows a 48-hour fasting event. To test this hypothesis, we studied the response of mice with genetic and pharmacological manipulations of the ghrelin/GHSR system to a fasting-refeeding protocol.

Materials and Methods

Animals

This study was performed using 3- to 5-month-old male mice generated in the animal facility of either the IMBICE (La Plata, Buenos Aires, Argentina) or the Centre de Psychiatrie et Neurosciences (Paris, France). Experimental mice included the following: (1) WT mice, on a pure C57BL/6 background, (2) GHSR-null mice, which do not express the GHSR (32), and (3) ghrelin-KO mice, which lack the preproghrelin gene (33). GHSR-null and ghrelin-KO mice were obtained from crosses between heterozygous animals backcrossed for >10 generations onto a C57BL/6 genetic background. Animals were maintained under controlled temperature (21°C) and photoperiod (12-hour light/dark cycle from 0600 to 1800) with regular chow and water available *ad libitum*. For fasting-refeeding studies, mice were housed individually under the same controlled conditions and maintained on a chow diet for 1 week before the experiments. Studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Research Council (United States) (34) and the European Communities Council Directive (86/609/European Economic Community). All experimentations received approval from the Institutional Animal Care and Use Committee of each institution.

Fasting-refeeding protocol

The overall experimental design for the fasting-refeeding protocol is diagrammed in Fig. 1. Initially, individually housed WT mice were either fed *ad libitum* ($n = 9$) or exposed to a fasting-refeeding protocol ($n = 17$), in which mice were




Figure 1. Overall experimental design. The figure summarizes the experimental design used in the current study. Mice were fasted by removing the chow diet from the home cages at 1000 and refed 48 hours later. WT mice were exposed to the fasting-refeeding protocol and studied at the different times of refeeding indicated over the time line. Mice, with genetic manipulation of the GHSR signaling, included GHSR-null mice and ghrelin-KO mice. Mice with pharmacological manipulations of the GHSR signaling included WT mice treated with either [D-Lys3]-growth hormone-releasing peptide 6 (GHRP-6), JMV2959, or K-(D-1-Nal)-FwLL-NH₂ during the fasting period. In particular, mice were intracerebroventricular (ICV) injected every 8 hours, starting at 1600 of the first day of fasting and finishing at 800 of the second day of fasting.

fasted by removing the chow diet from the home cages at 1000 and refed 48 hours later. Body weight and food intake were monitored daily and manually at 1000 for 7 days after refeeding. Food intake was calculated by subtracting the weight of the remaining food at 1000 by the weight of the initial food. In an independent study, acclimated and singly housed WT mice were either fed *ad libitum* (n = 4) or exposed to a fasting-refeeding protocol (n = 4) in cages placed in the Labmaster device (TSE Systems GmbH), which automatically monitors food intake and locomotor activity using feeding sensors and an infrared light beam-based system. In both cases, mice were monitored, at least, from the third day before fasting to the seventh day after fasting (experimental day 7).

In independent studies, WT mice were euthanized at 1000, at different experimental days along the fasting-refeeding protocol. In one experiment, mice were euthanized in *ad libitum*-fed (n = 6) or 2 days fasted (n = 6) conditions (hereafter, named fed and fasted groups, respectively), as well as after 2 (n = 6) or 4 (n = 6) days of refeeding (hereafter, referred as 2-d refed and 4-d refed groups, respectively). Here, blood samples were used to quantify plasma ghrelin and desacyl-ghrelin levels, whereas their brains were used to obtain ARC punches that were, in turn, used to quantify the mRNA levels of POMC, NPY, and GHSR genes. In another experiment, fed (n = 4), fasted (n = 7), 2-d refed (n = 4), and 4-d refed (n = 4) mice were used to estimate the presence of GHSR protein using the ghrelin binding assay described later. Finally, another set of fed (n = 7), fasted (n = 8), 2-d refed (n = 6), 4-d refed (n = 6), and 6-d refed (n = 6) mice were anesthetized and perfused with formalin to obtain their brains, which were used to perform immunostainings against NPY and POMC and estimate the levels of these food intake-regulating signals in the ARC.

Fasting-refeeding response in mice with genetic manipulations of the ghrelin system

GHSR-null mice (n = 11) and their WT littermates (n = 15) were exposed to the fasting-refeeding protocol, and their body weight and food intake were manually monitored, as described

previously. In other experiment, GHSR-null mice and their WT littermates were fed *ad libitum* (n = 6 and n = 7, respectively) or 2 days fasted (n = 7 and n = 8, respectively). On the morning of the experimental day, fed and fasted mice were anesthetized and perfused with formalin to obtain their brains for immunostaining. In another study, ghrelin-KO mice (n = 5) and their WT littermates (n = 7) were exposed to the fasting-refeeding protocol, and their body weight and food intake were automatically monitored, as described previously.

Fasting-refeeding response in mice with pharmacological manipulations of the GHSR signaling

For central infusion of drugs, mice were first stereotaxically implanted with a single indwelling guide cannula into the lateral ventricle [intracerebroventricular (ICV); placement coordinates: anteroposterior: -0.34, lateral: +1.0, and ventral: -2.3 mm]. After surgery, mice were individually housed and allowed to recover for at least 5 days. To block pharmacologically ghrelin-induced GHSR activation, WT mice were ICV treated during the fasting period with [D-Lys3]-growth hormone-releasing peptide 6 (GHRP-6; Cat. #SLBN1014V; Sigma-Aldrich) or JMV2959 [synthesized as previously described (35)]. In particular, mice were treated with vehicle (artificial cerebrospinal fluid) alone (n = 10) or containing [D-Lys3]-GHRP-6 (2 nmol/mouse, n = 5) or JMV2959 (3 nmol/mouse, n = 8) every 8 hours, starting at 1600 of the first day of fasting and finishing at 800 of the second day of fasting. Thus, each mouse received six ICV injections. Mice were refed at 1000, and body weight and food intake were manually monitored during refeeding, as described previously. The dose of [D-Lys3]-GHRP-6 was chosen based on a previous study (36) and on our own work, which showed that it reduced by $42.4 \pm 4.0\%$ the 2-hour food intake induced by 0.02 nmol/mouse of ICV-injected ghrelin. The dose of JMV2959 was chosen based on a previous study (37) and on our own work, which showed that it reduced a 2-hour food intake induced by ICV-injected ghrelin (0.02 nmol/mouse) by $72.0 \pm 12.8\%$. To block pharmacologically constitutive GHSR signaling, WT mice were ICV treated with K-(D-1-Nal)-FwLL-NH₂ during the fasting period. The K-(D-1-Nal)-FwLL-NH₂ is an inverse agonist that was synthesized by automated solid-phase peptide synthesis, as described elsewhere (16). Mice were treated with artificial cerebrospinal fluid alone (n = 12) or containing K-(D-1-Nal)-FwLL-NH₂ (1 nmol/mouse, n = 13) every 8 hours during the fasting period, as described previously. Mice were refed at 1000, and body weight and food intake were manually monitored during the refeeding period. The dose of K-(D-1-Nal)-FwLL-NH₂ was chosen based on a previous study (16) and on our own work, which showed the following: that (1) it significantly reduced *ad libitum* food intake in the early dark-phase period (from 1800 to 2300) when injected at 1800 (160.0 ± 41.3 mg vs 669.0 ± 123.7 mg, respectively) and (2) it reduced 2 hour food intake induced by ICV-injected ghrelin (0.02 nmol/mouse) by $81.0 \pm 5.6\%$. Importantly, the same dose of K-(D-1-Nal)-FwLL-NH₂ did not reduce *ad libitum* food intake in GHSR-null mice during the early dark-phase period when injected at 1800 (n = 5 each). Importantly, mice exposed to pharmacological manipulations in GHSR signaling did not show any sickness-like behavior, such as a spiky coat, hunched posture, altered

breathing rate, labored movements, reduced activity, and/or subdued behavior.

Determination of plasma ghrelin levels

Ghrelin and desacyl-ghrelin plasma concentrations were assayed by specific enzyme immunoassay (A05118 and A05117, respectively; Bertin Pharma). Blood samples were collected on EDTA (1 mg/mL final) and *p*-hydroxymercuribenzoic acid (0.4 mM final). Then, plasmas were immediately acidified with HCl (0.1 N final) to preserve acylation and stored frozen at -80°C .

Quantification of mRNA levels in hypothalamic punches

Brains were extracted, placed in cold diethylpyrocarbonate phosphate-buffered saline, and sectioned into 1 mm coronal slices by use of a mouse brain matrix. Punches of tissue corresponding to the location of the ARC, identified by comparing the coronal slices with a mouse brain atlas (38), were excised using a 15-gauge needle. Punches were collected in TRIzol reagent (Invitrogen), and total RNA was isolated, according to the manufacturer's protocol. The concentration and purity of RNA were estimated in a NanoDrop Lite Spectrophotometer (Thermo Scientific). One microgram of total RNA from each region was reverse transcribed into cDNA using random hexamer primers and Moloney murine leukemia virus reverse transcription (Promega). Quantitative polymerase chain reaction for NPY, POMC, and GHSR was performed in triplicate with HOT FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne), using a real-time polymerase chain reaction system StepOne Cycloer (Applied Biosystems). Product purity was confirmed by dissociation curves, and random samples were subjected to agarose gel electrophoresis. Fold change from fed values was determined using the relative standard curve method, normalizing the expression to the ribosomal protein L19 (reference gene). Primer sequences for NPY were sense: 5'-GCCAGATACTACTCCGCTCTG-3', antisense: 5'-GATCTCTTGCCATATCTCTGTCTG-3' (GenBank accession no. NM_023456.3), product size 68 bp. Primer sequences for POMC were sense: 5'-CCTCCTGCTTCAGACCTCCATA-3', antisense: 5'-TGTCATCTCCGTTGCCTGG-3' (GenBank accession no. NM_008895.3), product size 159 bp. Primer sequences for GHSR were sense: 5'-GCTCTGCAAACCTCTTCCA-3', antisense: 5'-AAGCAGATGGCGAAGTAG-3' (GenBank accession no. NM_177330.4), product size 99 bp. Primer sequences for ribosomal protein L19 were sense: 5'-AGCCTGTGACTGTC-CATTCC-3', antisense: 5'-TGGCAGTACCCTTCTCTTC-3' (GenBank accession no. NM_009078.2), product size 99 bp.

Immunohistochemistry

As previously described (39), brains of perfused mice were removed, postfixed, immersed in 20% sucrose, and cut coronally at 40 μm into three equal series on a sliding cryostat. To perform immunohistochemistry, sections were pretreated with 0.5% H_2O_2 , treated with blocking solution (3% normal donkey serum and 0.25% Triton-X), and incubated with a rabbit anti-NPY antibody (Table 1), rabbit anti-c-Fos (Table 1), or rabbit anti-POMC antibody (Table 1) for 48 hours at 4°C . Next, all sections were incubated with a biotinylated goat anti-rabbit antibody (Cat. #BA-1000; 1:3000; Vector Laboratories) and then with the Vectastain Elite ABC (Cat. #PK-6200; Vector Laboratories), according to the manufacturer's protocols. Finally, a visible signal was developed with diaminobenzidine (DAB)/nickel solution for NPY and c-Fos immunostainings, giving a black/purple precipitate and only with DAB for POMC immunostaining. Negative controls were also performed using the same procedure for each immunostaining but omitting either the primary antibody or secondary antibody. Sections were sequentially mounted on glass slides and coverslipped with mounting media.

Assessment of ghrelin-binding sites

A fluorescein-ghrelin(1–18) (hereafter referred to as F-ghrelin) tracer, provided by Dr. Luyt (University of Western Ontario, Canada) was used. F-Ghrelin is an 18-residues analog of the hormone with a fluorescein moiety attached at its C terminus. F-Ghrelin behaves similarly to endogenous ghrelin in terms of GHSR affinity and specificity (40, 41). Here, anesthetized mice were stereotaxically implanted with a single indwelling sterile guide cannula into the lateral ventricle and injected with F-ghrelin (60 pmol/mouse). Mice were perfused with formalin, 30 minutes after treatment, as described previously. Brains were processed, as described previously to generate coronal brain sections, which were then used for immunostaining against fluorescein using a goat anti-fluorescein antibody (Table 1) for 48 hours at 4°C . Then, sections were treated with a biotinylated donkey anti-goat antibody (Cat. #BA-5000; 1:1500; Vector Laboratories) and then with the Vectastain Elite ABC kit, according to the manufacturer's protocols. Finally, a visible signal was developed with DAB/nickel solution, giving a black/purple precipitate. Negative controls were also performed using the same procedure but omitting the primary or secondary antibodies. Sections were sequentially mounted on glass slides and coverslipped with mounting media.

Table 1. Antibodies Used

Peptide/Protein Target	Name of Antibody	Source	Species Raised in (Polyclonal)	Dilution Used	RRID
NPY	Neuropeptide Y antibody	Cat. #Ab30914 (Abcam)	Rabbit	1/30,000	AB_1566510
c-Fos	c-Fos (H-125) antibody	Cat. #sc-7202 (Santa Cruz Biotechnology)	Rabbit	1/2000	AB_2106765
Fluorescein/Oregon Green	Anti-fluorescein (fluorescein isothiocyanate)/Oregon Green	Cat. #A-11096 (Molecular Probes)	Goat	1/1500	AB_221558
POMC	POMC precursor (27–52) antibody	Cat. #H-029-30 (Phoenix Pharmaceuticals)	Rabbit	1/6000	AB_2307442

Abbreviation: RRID, research resource identifier.

Quantitative analysis

Low- and high-magnification bright-field images were acquired with a Nikon Eclipse 50i and a DS-Ri1 Nikon digital camera. Quantifications were bilaterally performed in digital high-magnification images of one complete series of coronal ARC sections between bregma -1.58 and -2.06 mm, using the anatomical limits, according to the mouse brain atlas (38). Total NPY-immunoreactive (IR) cells, POMC-IR cells, and c-Fos-IR cell nuclei were quantified, and data were expressed as IR cells per side. Fluorescein-IR signal was quantified as either positive cells or punctates; these data were expressed as IR cells per coronal section per side or IR-punctas/100 μm^2 . All data were corrected for double counting, according to the method of Abercrombie (42). The mean diameter of the positive signal was determined using Fiji. Blind quantitative analysis was performed independently by at least two observers.

Statistical analyses

Data are expressed as the means \pm standard error of the mean (SEM). Equality of variance was analyzed using Bartlett's or Levene's tests. When variances were equal, one-way analysis of variance (ANOVA), followed by the Tukey test, was used. When variances significantly differed, one-way ANOVA, followed by the Games-Howell test was used. Unpaired *t* test with Welch's correction was performed to compare cumulative food intake data of WT mice, ICV treated with each pharmacological manipulation and WT vs either GHSR-null or ghrelin-KO mice. Two-way ANOVA, followed by the Bonferroni test, was used to compare data from fasting-refeeding responses of WT, GHSR-null, ghrelin-KO, and WT ICV-treated mice. Differences were considered significant when $P < 0.05$.

Results

Daily food intake is affected in a long-term fashion after an event of fasting

First, we quantified food intake and body weight responses of WT mice under the fasting-refeeding protocol. Daily food intake was 3.43 ± 0.07 g/day in *ad libitum*-fed WT mice. As compared with fed mice, daily food intake of refeed mice significantly increased and remained elevated until day 5 of refeeding [Fig. 2(a)]. Cumulative food intake from day 1 to day 5 of refeeding was 24.07 ± 0.58 g, which represented an average of 3.48 ± 0.90 g/day for the overall period of fasting plus the 5 days of refeeding. The body weight of fasted mice significantly decreased at the end of the fasting period, compared with fed mice, and then fully recovered by day 3 of refeeding [Fig. 2(b)]. An independent set of WT mice tested in an automatized system showed an increase in the daily food intake that was also significantly higher until day 5 of refeeding, similarly as seen using the manual method. The automatized system, however, showed that most of the daily food intake of *ad libitum*-fed mice occurred in the dark cycle ($86.2 \pm 0.6\%$ of the total daily food intake) and that such pattern was unchanged through the study [Fig. 2(c)]. In refeed mice, daily food intake not only increased but

also changed its daily pattern [Fig. 2(c)]. As compared with food intake of fed mice, light-phase food intake of refeed mice significantly increased the first 6 days of refeeding [Fig. 2(d)], whereas dark-phase food intake of refeed mice significantly decreased in the same period of time [Fig. 2(e)].

ARC GHSR levels increased after an event of fasting

We then studied the impact of the fasting-refeeding protocol on plasma ghrelin levels and hypothalamic GHSR expression. As expected, plasma ghrelin and desacyl ghrelin levels were 1.9 ± 0.5 - and 1.8 ± 0.3 -fold higher in fasted mice compared with fed mice [Fig. 3(a) and (b)]. Plasma ghrelin levels decreased at 2 days of refeeding compared with levels detected in fasted mice. GHSR mRNA levels in the ARC were 3.1 ± 0.6 -fold higher in fasted mice, compared with fed mice, and then decreased in refeed mice [Fig. 3(c)]. To estimate the amount of GHSR protein, we used a F-ghrelin binding assay that provides distinct cell body-like and punctate labelings. The number of cell bodies binding F-ghrelin in the ARC was similar in all experimental groups (not shown). However, the density of F-ghrelin binding punctate in the ARC of fasted mice was 3.8 ± 0.6 -fold higher compared with *ad libitum*-fed mice. The density of F-ghrelin binding punctate in the ARC decreased after 2 days of refeeding, compared with the amount found in fasted mice, but remained 2.3 ± 0.2 -fold higher than the density found in the ARC of fed mice. The density of F-ghrelin binding punctate in the ARC at 4 days of refeeding was similar to the values found in fed mice [Fig. 3(d) and (e)].

As NPY is a key target of GHSR signaling in the ARC, we studied the effect of the fasting-refeeding protocol on the biosynthesis of this NPY. ARC NPY mRNA levels were 11.1 ± 2.9 -fold higher in fasted mice compared with fed mice [Fig. 4(a)]. After 2 days of refeeding, ARC NPY mRNA levels remained 6.4 ± 1.1 -fold higher than in fed mice. After 4 days of refeeding, ARC NPY mRNA levels were similar to fed mice. In terms of NPY peptide, most of the NPY-IR signal was observed with a dendritic localization, and few NPY-IR cell bodies were identified in the ARC of fed mice. The number of NPY-IR cells significantly increased in the ARC of fasted mice (46.4 ± 4.3 -fold higher compared with fed mice) and then decreased after 2 and 4 days of refeeding, compared with numbers detected in fasted mice, but remained 23.5 ± 3.7 - and 7.7 ± 1.4 -fold higher, respectively, compared with the values detected in fed mice [Fig. 4(b) and (c)]. After 6 days of refeeding, the number of NPY-IR cells in the ARC was similar to the number found in fed mice. POMC mRNA levels and the number of POMC-IR cells in the ARC were 0.5 ± 0.1 - and 0.5 ± 0.1 -fold smaller, respectively, in




Figure 2. Daily food intake is affected in a long-term fashion after an event of fasting. (a) and (b) Changes in food intake and body weight, respectively, of WT mice that were maintained with *ad libitum* access to regular chow (n = 9) or fasted for 2 days and then allowed free access to food at 10:00 AM (n = 17). (c) The daily feeding pattern monitored using an automated feeding/activity station (TSE system, GmbH). Light and dark phases are denoted by white and black rectangles on the x-axis. (d) and (e) Percentage of light- and dark-phase feeding, respectively (n = 4 for *ad libitum*-fed mice and n = 4 for refeed mice). Data represent the means \pm SEM and were compared by two-way ANOVA. *aP* < 0.05 vs *ad libitum*-fed mice on the same day.

fasted mice compared with fed mice [Fig. 4(d)–(f)]. However, POMC mRNA levels and the number POMC-IR cells in the ARC were not statistically different after 2 or more days of refeeding compared with fed mice.

GHSR signaling is required for a full compensatory hyperphagia

Then, we studied the food-intake response of GHSR-null mice to the fasting-refeeding protocol. Daily food




Figure 3. ARC GHSR binding sites but not circulating ghrelin remain increased several days after an event of fasting. (a) and (b) Plasma ghrelin and desacyl-ghrelin levels evaluated by specific enzyme immunoassay, respectively (n = 6 for each experimental group). (c) Comparative values of GHSR mRNA, relative to the ribosomal protein L19 gene, in ARC punches obtained from each experimental group (n = 6/group). (d) Bar graph displaying the quantitative analysis of the number of fluorescein-IR puncta per area unit in the ARC of each experimental group. (e) Representative photomicrographs of ARC coronal sections of ICV F-ghrelin-treated mice (n = 4–7/group) subjected to chromogenic immunostaining against fluorescein. Insets in each image show high magnification of areas marked in low magnification images. Arrows and arrowheads point to fluorescein-IR somas and puncta, respectively. Original scale bars, 100 and 10 μ m for the low and high magnification images, respectively. Data represent the means \pm SEM and were compared by one-way ANOVA. *aP* < 0.05 vs *ad libitum*-fed mice; *bP* < 0.05 vs fasted mice.

intake of refeed GHSR-null mice significantly increased and remained elevated until day 5 of refeeding, as seen in WT mice [Fig. 5(a)]. However, cumulative food intake in GHSR-null mice between days 1 and 5 of refeeding was decreased by $14.4\% \pm 3.5\%$ compared with WT mice [Fig. 5(b)]. Body weights of WT and GHSR-null mice did not differ throughout the experiment [Fig. 5(c)]. An independent set of WT and GHSR-null mice exposed to fasting showed that the number of both NPY-IR cells and c-Fos-IR cells was significantly reduced in the ARC of fasted GHSR-null mice compared with the numbers found in the ARC of fasted WT mice [Fig. 5(d)–(g)].

Constitutive, but not ghrelin-evoked, GHSR signaling is required for a full compensatory hyperphagia

Then, we studied the response to the fasting-refeeding protocol of mice with other manipulations of the ghrelin system. We found that daily food intake, as well as the compensatory hyperphagia, after the fasting period of ghrelin-KO mice [Fig. 6(a) and (b)] and of WT mice treated with the GHSR antagonists [D-Lys3]-GHRP-6 or JMV2959 [Fig. 6(c) and (d)] was similar compared with the control group. The daily food intake of refeed WT mice treated with the GHSR inverse agonist K-(D-1-Nal)-




Figure 4. ARC NPY levels increased and POMC levels decreased after an event of fasting. (a) and (d) Comparative values of NPY and POMC mRNA, respectively, relative to the ribosomal protein L19 gene, in ARC punches obtained from each experimental group ($n = 6$ /group). (c) and (f) Representative photomicrographs of ARC coronal sections of mice in each experimental group ($n = 6$ – 8 /group) subjected to chromogenic immunostaining against NPY and POMC, respectively. Insets in each image show high magnification of areas marked in low magnification images. Arrows point to NPY- or POMC-IR cells. Original scale bars, 100 and 10 μm for the low and high magnification images, respectively. (b) and (e) Bar graphs displaying the quantitative analysis of the number of NPY and POMC cells, respectively, in the ARC of each experimental group. Data represent the means \pm SEM and were compared by one-way ANOVA test. $aP < 0.05$ vs *ad libitum*-fed mice; $bP < 0.05$ vs fasted mice.

FwLL-NH₂ significantly increased and remained elevated until day 5 of refeeding, but the cumulative food intake between days 1 and 5 was significantly decreased by 14.8% \pm 3.8% in K-(D-1-Nal)-FwLL-NH₂-treated mice compared with vehicle-treated mice [Fig. 6(e) and (f)]. In

an independent set of mice treated with either vehicle or K-(D-1-Nal)-FwLL-NH₂ during the fasting period, the number of both NPY-IR and c-Fos-IR cells in the ARC was significantly reduced in fasted mice treated with K-




Figure 5. GHSR signaling is required to display a full fasting-induced hyperphagia. (a) and (c) Changes in food intake and body weight, respectively, of WT ($n = 15$) and GHSR-null ($n = 11$) mice during 2 days of fasting and refeeding, as described in Fig. 1. Data represent the means \pm SEM and were compared by two-way ANOVA. (b) The 5-day cumulative food intake during refeeding of WT and GHSR-null mice, respectively. Data represent the means \pm SEM and were compared by unpaired t test with Welch's correction. $a P < 0.05$ vs WT mice. (e) and (g) Representative photomicrographs of ARC coronal sections of WT and GHSR-null mice, respectively, belong to *ad libitum*-fed and fasted groups, subjected to chromogenic immunostaining against NPY and c-Fos, respectively. Arrows point to NPY-IR cells. Original scale bars, 100 and 10 μ m for the low and high magnification images, respectively. (d) and (f) Bar graphs displaying the quantitative analysis of the number of NPY-IR and c-Fos-IR cells, respectively, in the ARC of each experimental group. Data represent the means \pm SEM and were compared by two-way ANOVA. $aP < 0.05$ vs WT mice under fasting conditions.

(D-1-Nal)-FwLL-NH₂ compared with the numbers found in fasted mice treated with vehicle [Fig. 6(g)–(j)].

Discussion

In vitro studies, using heterologous expression systems or lipid discs, have shown that GHSR displays an unusually high constitutive activity that signals with $\sim 50\%$ of its maximal capacity in the absence of ghrelin (11, 43–45). In addition, the constitutive GHSR activity has been shown to affect growth hormone secretion in human somatotroph adenomas *in vitro* (12). Whether GHSR displays *in vivo* ghrelin-independent signaling is unknown; however,

some naturally occurring GHSR mutations that impair its constitutive activity have been linked to short stature in human populations, suggesting that constitutive GHSR activity may be physiologically relevant (18, 19). As indicated in the Introduction, some pharmacological or genetic manipulations of the ghrelin/GHSR system in mouse models also provided circumstantial evidence that the constitutive GHSR activity plays a role in regulating body weight and/or food intake. However, observations have been subtle and inconsistent in *ad libitum*-fed conditions. Thus, the relevance of ghrelin-independent GHSR signaling on food intake regulation has remained uncertain. It is well established that the ghrelin/GHSR




Figure 6. Central administration of the GHSR inverse agonist K-(D-1-Nal)-FwLL-NH₂, but not genetic deficiency of ghrelin or GHSR antagonists, impairs the fasting-induced hyperphagia. (a), (c), and (e) Changes in food intake of WT ($n = 7$) or ghrelin-KO ($n = 5$) mice; WT mice ICV treated with vehicle ($n = 7$) or with the GHSR antagonists D-Lys(3)-GHRP-6 ($n = 5$) or JMV2959 ($n = 8$); and WT mice ICV treated with vehicle ($n = 12$) or with the GHSR inverse agonist K-(D-1-Nal)-FwLL-NH₂ ($n = 13$), respectively. Mice were fasted and refed as described in Fig. 1. Data represent the means \pm SEM and were compared by two-way ANOVA. (b), (d), and (f) The 5-day cumulative food intake during refeeding of WT or ghrelin-KO mice; WT mice ICV treated with vehicle, D-Lys(3)-GHRP-6, or JMV2959; and WT mice ICV treated with vehicle or with K-(D-1-Nal)-FwLL-NH₂, respectively. Data represent the means \pm SEM and

system becomes more relevant under conditions of energy deficit, such as 48-hour fasting, a situation where plasma ghrelin levels, as well as the hypothalamic expression of GHSR, are increased (23, 24). Notably, hypothalamic GHSR mRNA levels, as well as the sensitivity to ghrelin, seem to be higher in mice fasted for longer periods of time (24, 27). Thus, we reasoned the following: that (1) the central GHSR signaling is likely to be increased when hypothalamic GHSR expression levels are high and (2) the refeeding period that follows a 48-hour fasting event would be an interesting condition to unmask a potential effect of constitutive GHSR signaling on food intake regulation.

Here, we confirmed that mice display several days of hyperphagia after an event of fasting and then return to basal food-intake levels, as previously reported (46, 47). Interestingly, the extra amount of calories that refed mice ingested during the fasting-induced hyperphagia period exactly matched the amount of calories that mice did not consume during the fasting period. Thus, the compensatory hyperphagia seems to depend on homeostatic aspects of feeding, which drive food intake according to energy balance. Notably, ghrelin levels increased in fasted mice and quickly returned to basal levels when the fasting state was over, as expected based on the short half-life of circulating ghrelin (48). Indeed, ghrelin levels in fasted rats return to basal levels a few hours after refeeding (22, 49, 50). GHSR mRNA levels have been shown to be increased in the ARC of fasted mice and rats (44, 51). A more recent study showed that GHSR mRNA levels are ~ 3.4 -fold increased, specifically within ARC NPY/AgRP neurons (25, 52). In line with these observations, the ghrelin-induced increase in the number of c-Fos-IR cells in the ARC has been shown to be higher in fasted animals (26). Here, we not only confirmed that ARC GHSR

mRNA levels increased in fasted mice but also showed that ghrelin binding increased in the ARC of these animals, suggesting that gene transcription results in GHSR protein biosynthesis. We did not detect an increase in the number of ghrelin binding cells in the ARC of fasted mice, but rather, we detected an increase in the presynaptic bouton-like shape-labeling in this hypothalamic region. Ghrelin binding has been already shown in the NPY and γ -aminobutyric acid synaptic terminals within the ARC and its targets (e.g., the hypothalamic paraventricular nucleus), respectively, where it regulates neurotransmitter release via the regulation of presynaptic calcium channels (28, 44, 53, 54). Here, we found that the NPY-IR signal displayed a dendritic localization in the ARC of fed mice but had both a dendritic and a cell body localization in the ARC of fasted mice. These observations, together with the fact that the NPY mRNA levels were increased in the ARC of fasted mice, suggest that the NPY biosynthesis is increased during fasting. In parallel, POMC mRNA levels and the number of POMC-IR cells were decreased in the ARC of fasted mice. Thus, it can be hypothesized that the fasting-induced increase in GHSR signaling promotes ARC NPY/AgRP neuron activation, which in turn, inhibits the ARC POMC neurons (28). Interestingly, ARC GHSR mRNA levels returned to basal levels at day 2 of refeeding, whereas the density of ghrelin binding sites in the ARC remained elevated at this time point and returned to basal levels at day 4 of refeeding. In addition, we found that the NPY levels remained elevated at days 2 and 4 of refeeding, whereas POMC levels returned to fed levels after refeeding. To our knowledge, the *in vivo* half-lives of the GHSR mRNA and protein have not been estimated. As the half-life for other GPCRs, such as the κ -opioid receptor, has been estimated to several days (55), it seems reasonable to hypothesize that GHSR mRNA gene expression in the ARC returns to basal levels when the fasting state is over, whereas the GHSR protein remains present in NPY/AgRP neurons for a longer time period. Such increments of GHSR levels in ARC NPY/AgRP neurons at the first days of refeeding

would impact NPY biosynthesis and as a consequence, feeding behavior.

To test if the behavioral and neuronal changes detected at the first days of refeeding require GHSR signaling, we studied GHSR-deficient mice. Mice lacking GHSR displayed a smaller hyperphagia during the refeeding period compared with WT mice. In parallel, the increments of the NPY levels and the neuronal activation, as indicated by c-Fos signal, in the ARC of fasted GHSR-null mice were also smaller compared with fasted WT mice. These observations indicate that GHSR signaling is required to display the full compensatory hyperphagia that follows a fasting event. Remarkably, GHSR-null mice displayed fasting-induced hyperphagia and showed a subtle decrease in their total cumulative food intake during the refeeding period (~15%) without substantial differences in body weight compared with refed WT mice. Such results are not unexpected, as a result of inherent redundancies in the mechanisms responsible for body weight homeostasis-related food intake in which many hormonal [e.g., leptin (46)] and metabolic [e.g. glucose (56)] systems are involved (57). It is interesting to note that stress strongly influences eating behaviors and that ghrelin signaling also modulates the response to stress (39, 58, 59). Thus, the smaller fasting-induced hyperphagia observed in GHSR-null mice may be impacted by a different susceptibility to fasting-induced stress of these animals. Further studies are required to investigate this aspect of the study in detail. Notably, a previous study did not detect differences in food intake of WT and GHSR-KO mice exposed to a fasting-refeeding paradigm similar to the one used in the current study (60). However, the study to which we refer was performed with mice previously fed a high-fat diet that weighed ~40 to 45 g, whereas we used young mice ranging from 22 to 25 g of body weight, fed with regular chow diet. As obese and/or aged mice are less prone to adapt to metabolic changes (61), it is likely that such differences may explain the diverse outcomes of the studies.

Mice lacking the ghrelin gene and mice centrally treated with two unrelated GHSR antagonists displayed a full compensatory hyperphagia after a fasting event. Some, but not all, previous studies using different pharmacological strategies (e.g., anti-ghrelin RNA spiegelmers, anti-ghrelin antibodies, GHSR antagonists) have shown that the action of endogenous ghrelin is required for the fasting-induced hyperphagia (8, 62–66). The reason for these discrepancies is unknown, although differences between experimental designs (e.g., dose, administration protocols) are likely among the critical factors that impact the results. To our knowledge, no adverse effects have been reported for the tested GHSR

Figure 6. (Continued). were compared by unpaired *t* test with Welch's correction. $aP < 0.05$ vs WT mice ICV treated with vehicle. (h) and (j) Representative photomicrographs of ARC coronal sections of WT mice ICV treated with vehicle or K-(D-1-Nal)-FwLL-NH₂ during the fasting period, subjected to chromogenic immunostaining against NPY and c-Fos, respectively. Arrows point to NPY-IR cells. Original scale bars, 100 and 10 μ m for the low and high magnification images, respectively. (g) and (i) Bar graphs displaying the quantitative analysis of the number of NPY-IR cells and c-Fos-IR cells, respectively, in the ARC of each experimental group. Data represent the means \pm SEM and were compared by unpaired *t* test with Welch's correction. $aP < 0.05$ vs WT mice ICV treated with vehicle.

ligand; however, toxicity is always a concern when drugs are centrally administered. For the current study, pharmacological tests were carefully set up, and mice were treated with the maximum dose of GHSR antagonists that did not induce any sign of sickness-like behavior to avoid nonspecific effects of the compounds on food intake. Under these experimental conditions, GHSR antagonists successfully, but partially, blocked the orexigenic effect of exogenously administered ghrelin. The fact that not only two completely unrelated GHSR antagonists but also the genetic deficiency of endogenous ghrelin failed to affect the compensatory hyperphagia after a fasting event suggests that the ghrelin-evoked GHSR activation was not required for such behavior. Interestingly, we found that mice centrally treated with K-(D-1-Nal)-FwLL-NH₂ displayed a smaller compensatory hyperphagia after fasting compared with mice treated with vehicle. Importantly, the extent to which this pharmacological treatment impacted hypothalamic, constitutive GHSR activity cannot be directly measured; however, the observation that WT mice treated with K-(D-1-Nal)-FwLL-NH₂ and GHSR-null mice displayed a similar reduction of the fasting-induced hyperphagia suggests that this GHSR inverse agonist fully abrogated the receptor activity. It is interesting to stress that fasted mice were centrally treated with K-(D-1-Nal)-FwLL-NH₂ exclusively during the fasting period and that they displayed smaller increments of both NPY levels and neuronal activation in the ARC at the end of the fasting period. Thus, GHSR activity seems to play a role during both fasting and refeeding periods. The fact that K-(D-1-Nal)-FwLL-NH₂ did not affect the food intake of GHSR-null mice strongly indicated that the effects were specific. Notably, K-(D-1-Nal)-FwLL-NH₂ partially blocked ghrelin-induced food intake (see Materials and Methods), suggesting that this GHSR ligand may also affect the ghrelin-evoked GHSR activation; however, the observations that the compensatory hyperphagia after fasting was not affected in ghrelin-KO mice and in mice treated with GHSR antagonists suggest that this eating behavior is independent of the action of ghrelin.

Given the high constitutive activity of GHSR, both antagonism and inverse agonism properties should be taken in consideration when testing GHSR ligands as potential drugs for clinical use. Here, we found evidence that the decrease in GHSR signaling in mice mitigates the hyperphagia that follows an event of food deprivation. Further studies are necessary to test if changes in GHSR signaling also contribute to the mechanisms controlling long-term body weight after chronic caloric restriction. Notably, a recent study showed that the suppression of ghrelin signaling in obese mice prevents postdieting body weight rebound, a problem commonly observed in dieters

(67). Thus, treatments capable of blocking constitutive GHSR signaling may help to maintain a reduced calorie intake after dieting and contribute to the long-term management of obese patients (68). Further studies are required to test if the suppression of ghrelin signaling is also useful to treat other eating disorders that have been linked to ghrelin signaling, such as binge eating (69, 70). Importantly, an oral GHSR inverse agonist, named PF-05190457, has been recently developed and already tested in patients (71, 72). Thus, our observations in a mouse model may have clinical applications in the near future.

Acknowledgments

We thank MinCyT-ECOS-Sud (A13B01) and Bec.Ar for support covering exchanges, Dr. Jeff Zigman (University of Texas Southwestern Medical Center, Dallas, TX) for providing the GHSR-null mice, and Dr. Catherine Tomasetto (Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, France) for providing the ghrelin-KO mice. The technical assistance of Dr. María Jose Tolosa, Dr. Guadalupe García-Romero, and Lic. Mirta Reynaldo is also acknowledged.

Financial Support: This work was supported by the PICTO2013-0065 grant, which is cofinanced by the National Agency of Scientific and Technological Promotion of Argentina and GlaxoSmithKline (to M.P.) and by grants of the INSERM and Agence Nationale pour la Recherche (ANR-12-JSV1-0013-01; to V.T.). G.F. was supported by CONICET.

Q:10

Correspondence: Mario Perello, PhD, Laboratory of Neurophysiology, Multidisciplinary Institute of Cell Biology, Calle 526 S/N entre 10 y 11-PO Box 403, La Plata, Buenos Aires 1900, Argentina. E-mail: mperello@imbice.gov.ar.

Q:11

Disclosure Summary: The authors have nothing to disclose.

References

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature*. 1999;402(6762):656–660.
2. Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, D'Alessio D, Depoortere I, Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S, Dickson SL, Diéguez C, Granata R, Grill HJ, Grove K, Habegger KM, Heppner K, Heiman ML, Holsen L, Holst B, Inui A, Jansson JO, Kirchner H, Korbonsits M, Laferrère B, LeRoux CW, Lopez M, Morin S, Nakazato M, Nass R, Perez-Tilve D, Pfluger PT, Schwartz TW, Seeley RJ, Sleeman M, Sun Y, Sussel L, Tong J, Thorner MO, van der Lely AJ, van der Ploeg LH, Zigman JM, Kojima M, Kangawa K, Smith RG, Horvath T, Tschöp MH. Ghrelin. *Mol Metab*. 2015;4(6):437–460.
3. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. *Diabetes*. 2001;50(8):1714–1719.
4. Nass R, Farhy LS, Liu J, Prudom CE, Johnson ML, Veldhuis P, Pezzoli SS, Oliveri MC, Gaylinn BD, Geysen HM, Thorner MO.

- Evidence for acyl-ghrelin modulation of growth hormone release in the fed state. *J Clin Endocrinol Metab.* 2008;**93**(5):1988–1994.
5. Howard AD, Feighner SD, Cully DF, Arena JP, Liberators PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevich M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH. A receptor in pituitary and hypothalamus that functions in growth hormone release. *Science.* 1996;**273**(5277):974–977.
 6. Wang Q, Liu C, Uchida A, Chuang JC, Walker A, Liu T, Osborne-Lawrence S, Mason BL, Mosher C, Berglund ED, Elmquist JK, Zigman JM. Arcuate AgRP neurons mediate orexigenic and glucoregulatory actions of ghrelin. *Mol Metab.* 2013;**3**(1):64–72.
 7. Cabral A, Valdivia S, Fernandez G, Reynaldo M, Perello M. Divergent neuronal circuitries underlying acute orexigenic effects of peripheral or central ghrelin: critical role of brain accessibility. *J Neuroendocrinol.* 2014;**26**(8):542–554.
 8. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. *Nature.* 2001;**409**(6817):194–198.
 9. Luquet S, Phillips CT, Palmiter RD. NPY/AgRP neurons are not essential for feeding responses to glucoprivation. *Peptides.* 2007;**28**(2):214–225.
 10. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwartz TW. Common structural basis for constitutive activity of the ghrelin receptor family. *J Biol Chem.* 2004;**279**(51):53806–53817.
 11. Damian M, Marie J, Leyris JP, Fehrentz JA, Verdié P, Martinez J, Banères JL, Mary S. High constitutive activity is an intrinsic feature of ghrelin receptor protein: a study with a functional monomeric GHS-R1a receptor reconstituted in lipid discs. *J Biol Chem.* 2012;**287**(6):3630–3641.
 12. Mear Y, Enjalbert A, Thirion S. GHS-R1a constitutive activity and its physiological relevance. *Front Neurosci.* 2013;**7**:87.
 13. Petersen PS, Woldbye DP, Madsen AN, Egerod KL, Jin C, Lang M, Rasmussen M, Beck-Sickinger AG, Holst B. In vivo characterization of high basal signaling from the ghrelin receptor. *Endocrinology.* 2009;**150**(11):4920–4930.
 14. Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. *J Biol Chem.* 1998;**273**(5):3097–3104.
 15. Holst B, Lang M, Brandt E, Bach A, Howard A, Frimurer TM, Beck-Sickinger A, Schwartz TW. Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. *Mol Pharmacol.* 2006;**70**(3):936–946.
 16. Els S, Schild E, Petersen PS, Kilian TM, Mokrosinski J, Frimurer TM, Chollet C, Schwartz TW, Holst B, Beck-Sickinger AG. An aromatic region to induce a switch between agonism and inverse agonism at the ghrelin receptor. *J Med Chem.* 2012;**55**(17):7437–7449.
 17. Uchida A, Zigman JM, Perelló M. Ghrelin and eating behavior: evidence and insights from genetically-modified mouse models. *Front Neurosci.* 2013;**7**:121.
 18. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, Morisset S, Nivot S, Vie-Luton MP, Grouselle D, de Kerdanet M, Kadiri A, Epelbaum J, Le Bouc Y, Amsellem S. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. *J Clin Invest.* 2006;**116**(3):760–768.
 19. Inoue H, Kangawa N, Kinouchi A, Sakamoto Y, Kimura C, Horikawa R, Shigematsu Y, Itakura M, Ogata T, Fujieda K; Japan Growth Genome Consortium. Identification and functional analysis of novel human growth hormone secretagogue receptor (GHSR) gene mutations in Japanese subjects with short stature. *J Clin Endocrinol Metab.* 2011;**96**(2):E373–E378.
 20. Goldstein JL, Zhao TJ, Li RL, Sherbet DP, Liang G, Brown MS. Surviving starvation: essential role of the ghrelin-growth hormone axis. *Cold Spring Harb Symp Quant Biol.* 2011;**76**(0):121–127.
 21. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. *J Clin Endocrinol Metab.* 2001;**86**(10):4753–4758.
 22. Steyn FJ, Leong JW, Huang L, Tan HY, Xie TY, Nelson C, Waters MJ, Veldhuis JD, Epelbaum J, Chen C. GH does not modulate the early fasting-induced release of free fatty acids in mice. *Endocrinology.* 2012;**153**(1):273–282.
 23. Kim MS, Yoon CY, Park KH, Shin CS, Park KS, Kim SY, Cho BY, Lee HK. Changes in ghrelin and ghrelin receptor expression according to feeding status. *Neuroreport.* 2003;**14**(10):1317–1320.
 24. Luque RM, Park S, Kineman RD. Severity of the catabolic condition differentially modulates hypothalamic expression of growth hormone-releasing hormone in the fasted mouse: potential role of neuropeptide Y and corticotropin-releasing hormone. *Endocrinology.* 2007;**148**(1):300–309.
 25. Henry FE, Sugino K, Tozer A, Branco T, Sternson SM. Cell type-specific transcriptomics of hypothalamic energy-sensing neuron responses to weight-loss. *eLife.* 2015;**4**:e09800.
 26. Luckman SM, Rosenzweig I, Dickson SL. Activation of arcuate nucleus neurons by systemic administration of leptin and growth hormone-releasing peptide-6 in normal and fasted rats. *Neuroendocrinology.* 1999;**70**(2):93–100.
 27. Cabral A, Cornejo MP, Fernandez G, De Francesco PN, Garcia-Romero G, Uriarte M, Zigman JM, Portiansky E, Reynaldo M, Perello M. Circulating ghrelin acts on GABA neurons of the area postrema and mediates gastric emptying in male mice. *Endocrinology.* 2017;**158**(5):1436–1449.
 28. Atasoy D, Betley JN, Su HH, Sternson SM. Deconstruction of a neural circuit for hunger. *Nature.* 2012;**488**(7410):172–177.
 29. Takahashi KA, Cone RD. Fasting induces a large, leptin-dependent increase in the intrinsic action potential frequency of orexigenic arcuate nucleus neuropeptide Y/agouti-related protein neurons. *Endocrinology.* 2005;**146**(3):1043–1047.
 30. Perello M, Stuart RC, Nillni EA. Differential effects of fasting and leptin on proopiomelanocortin peptides in the arcuate nucleus and in the nucleus of the solitary tract. *Am J Physiol Endocrinol Metab.* 2007;**292**(5):E1348–E1357.
 31. Segal-Lieberman G, Trombly DJ, Juthani V, Wang X, Maratos-Flier E. NPY ablation in C57BL/6 mice leads to mild obesity and to an impaired refeeding response to fasting. *Am J Physiol Endocrinol Metab.* 2003;**284**(6):E1131–E1139.
 32. Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK. Expression of ghrelin receptor mRNA in the rat and the mouse brain. *J Comp Neurol.* 2006;**494**(3):528–548.
 33. Hassouna R, Zizzari P, Tomasetto C, Veldhuis JD, Fiquet O, Labarthe A, Cognet J, Steyn F, Chen C, Epelbaum J, Tolle V. An early reduction in GH peak amplitude in preproghrelin-deficient male mice has a minor impact on linear growth. *Endocrinology.* 2014;**155**(9):3561–3571.
 34. *Guide for the Care and Use of Laboratory Animals.* 8th ed. Washington, DC: The National Academies Press; 2011.
 35. Moulin A, Demange L, Bergé G, Gagne D, Ryan J, Mousseaux D, Heitz A, Perrissoud D, Locatelli V, Torsello A, Galleyrand JC, Fehrentz JA, Martinez J. Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluations. *J Med Chem.* 2007;**50**(23):5790–5806.
 36. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, Kasuga M. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. *Gut.* 2003;**52**(7):947–952.

37. Salomé N, Haage D, Perrissoud D, Moulin A, Demange L, Eggecioglu E, Fehrentz JA, Martinez J, Dickson SL. Anorexigenic and electrophysiological actions of novel ghrelin receptor (GHS-R1A) antagonists in rats. *Eur J Pharmacol.* 2009;612(1-3):167–173.
38. Paxinos G, Franklin KBJ. *The Mouse Brain in Stereotaxic Coordinates*. 2nd ed. San Diego: Academic Press; 2001.
39. Cabral A, Suescun O, Zigman JM, Perello M. Ghrelin indirectly activates hypophysiotropic CRF neurons in rodents. *PLoS One.* 2012;7(2):e31462.
40. McGirr R, McFarland MS, McTavish J, Luyt LG, Dhanvantari S. Design and characterization of a fluorescent ghrelin analog for imaging the growth hormone secretagogue receptor 1a. *Regul Pept.* 2011;172(1-3):69–76.
41. Cabral A, Fernandez G, Perello M. Analysis of brain nuclei accessible to ghrelin present in the cerebrospinal fluid. *Neuroscience.* 2013;253:406–415.
42. Valdivia S, Patrone A, Reynaldo M, Perello M. Acute high fat diet consumption activates the mesolimbic circuit and requires orexin signaling in a mouse model [published correction appears in *PLoS One.* 2004;9(3):e92932]. *PLoS One.* 2014;9(1):e87478.
43. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High constitutive signaling of the ghrelin receptor—identification of a potent inverse agonist. *Mol Endocrinol.* 2003;17(11):2201–2210.
44. López Soto EJ, Agosti F, Cabral A, Mustafa ER, Damonte VM, Gandini MA, Rodríguez S, Castrogiovanni D, Felix R, Perelló M, Raingo J. Constitutive and ghrelin-dependent GHSR1a activation impairs CaV2.1 and CaV2.2 currents in hypothalamic neurons. *J Gen Physiol.* 2015;146(3):205–219.
45. Mustafá ER, López Soto EJ, Martínez Damonte V, Rodríguez SS, Lipscombe D, Raingo J. Constitutive activity of the ghrelin receptor reduces surface expression of voltage-gated Ca²⁺ channels in a CaV β -dependent manner. *J Cell Sci.* 2017;130(22):3907–3917.
46. Pedroso JA, Silveira MA, Lima LB, Furigo IC, Zampieri TT, Ramos-Lobo AM, Buonfiglio DC, Teixeira PD, Frazão R, Donato J, Jr. Changes in leptin signaling by SOCS3 modulate fasting-induced hyperphagia and weight regain in mice. *Endocrinology.* 2016;157(10):3901–3914.
47. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. *Nature.* 1996;381(6581):415–421.
48. Akamizu T, Takaya K, Irako T, Hosoda H, Teramukai S, Matsuyama A, Tada H, Miura K, Shimizu A, Fukushima M, Yokode M, Tanaka K, Kangawa K. Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. *Eur J Endocrinol.* 2004;150(4):447–455.
49. Guo ZF, Ren AJ, Zheng X, Qin YW, Cheng F, Zhang J, Wu H, Yuan WJ, Zou L. Different responses of circulating ghrelin, obestatin levels to fasting, re-feeding and different food compositions, and their local expressions in rats. *Peptides.* 2008;29(7):1247–1254.
50. Zizzari P, Hassouna R, Longchamps R, Epelbaum J, Tolle V. Meal anticipatory rise in acylated ghrelin at dark onset is blunted after long-term fasting in rats. *J Neuroendocrinol.* 2011;23(9):804–814.
51. Nogueiras R, Tovar S, Mitchell SE, Rayner DV, Archer ZA, Dieguez C, Williams LM. Regulation of growth hormone secretagogue receptor gene expression in the arcuate nuclei of the rat by leptin and ghrelin. *Diabetes.* 2004;53(10):2552–2558.
52. Yasrebi A, Hsieh A, Mamounis KJ, Krumm EA, Yang JA, Magby J, Hu P, Roepke TA. Differential gene regulation of GHSR signaling pathway in the arcuate nucleus and NPY neurons by fasting, diet-induced obesity, and 17 β -estradiol [published correction appears in *Mol Cell Endocrinol.* 2016;428:171–173]. *Mol Cell Endocrinol.* 2016;422:42–56.
53. Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. *Neuron.* 2003;37(4):649–661.
54. Cabral A, Portiansky E, Sánchez-Jaramillo E, Zigman JM, Perello M. Ghrelin activates hypophysiotropic corticotropin-releasing factor neurons independently of the arcuate nucleus. *Psychoneuroendocrinology.* 2016;67:27–39.
55. Polter AM, Barcomb K, Chen RW, Dingess PM, Graziane NM, Brown TE, Kauer JA. Constitutive activation of kappa opioid receptors at ventral tegmental area inhibitory synapses following acute stress. *eLife.* 2017;6:e23785.
56. Becskei C, Lutz TA, Riediger T. Glucose reverses fasting-induced activation in the arcuate nucleus of mice. *Neuroreport.* 2008;19(1):105–109.
57. Karatsoreos IN, Thaler JP, Borgland SL, Champagne FA, Hurd YL, Hill MN. Food for thought: hormonal, experiential, and neural influences on feeding and obesity. *J Neurosci.* 2013;33(45):17610–17616.
58. Spencer SJ, Xu L, Clarke MA, Lemus M, Reichenbach A, Geenen B, Koizic T, Andrews ZB. Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress. *Biol Psychiatry.* 2012;72(6):457–465.
59. Chuang JC, Perello M, Sakata I, Osborne-Lawrence S, Savitt JM, Lutter M, Zigman JM. Ghrelin mediates stress-induced food-reward behavior in mice. *J Clin Invest.* 2011;121(7):2684–2692.
60. Sun Y, Butte NF, Garcia JM, Smith RG. Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. *Endocrinology.* 2008;149(2):843–850.
61. Steinhagen-Thiessen E, Reznick AZ, Hilz H. Positive and negative adaptation of muscle enzymes in aging mice subjected to physical exercise. *Mech Ageing Dev.* 1981;16(4):363–369.
62. Mayorov AV, Amara N, Chang JY, Moss JA, Hixon MS, Ruiz DI, Meijler MM, Zorrilla EP, Janda KD. Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice. *Proc Natl Acad Sci USA.* 2008;105(45):17487–17492.
63. Zakhari JS, Zorrilla EP, Zhou B, Mayorov AV, Janda KD. Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. *Mol Pharm.* 2012;9(2):281–289.
64. Perello M, Sakata I, Birnbaum S, Chuang JC, Osborne-Lawrence S, Rovinsky SA, Woloszyn J, Yanagisawa M, Lutter M, Zigman JM. Ghrelin increases the rewarding value of high-fat diet in an orexin-dependent manner. *Biol Psychiatry.* 2010;67(9):880–886.
65. Becskei C, Bilik KU, Klusmann S, Jarosch F, Lutz TA, Riediger T. The anti-ghrelin Spiegelmer NOX-B11-3 blocks ghrelin- but not fasting-induced neuronal activation in the hypothalamic arcuate nucleus. *J Neuroendocrinol.* 2008;20(1):85–92.
66. Thomas MA, Ryu V, Bartness TJ. Central ghrelin increases food foraging/hoarding that is blocked by GHSR antagonism and attenuates hypothalamic paraventricular nucleus neuronal activation. *Am J Physiol Regul Integr Comp Physiol.* 2016;310(3):R275–R285.
67. Chen VP, Gao Y, Geng L, Brimijoin S. Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling. *Proc Natl Acad Sci USA.* 2017;114(41):10960–10965.
68. Cameron KO, Bhattacharya SK, Loomis AK. Small molecule ghrelin receptor inverse agonists and antagonists. *J Med Chem.* 2014;57(21):8671–8691.
69. Geliebter A, Hashim SA, Gluck ME. Appetite-related gut peptides, ghrelin, PYY, and GLP-1 in obese women with and without binge eating disorder (BED). *Physiol Behav.* 2008;94(5):696–699.
70. Valdivia S, Cornejo MP, Reynaldo M, De Francesco PN, Perello M. Escalation in high fat intake in a binge eating model differentially engages dopamine neurons of the ventral tegmental area and requires ghrelin signaling. *Psychoneuroendocrinology.* 2015;60:206–216.

71. Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, Tuthill T, Jackson VM. Pharmacokinetics and pharmacodynamics of PF-05190457: the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. *Br J Clin Pharmacol.* 2017;**83**(2): 326–338.
72. Kong J, Chuddy J, Stock IA, Loria PM, Straub SV, Vage C, Cameron KO, Bhattacharya SK, Lapham K, McClure KF, Zhang Y, Jackson VM. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo. *Br J Pharmacol.* 2016;**173**(9):1452–1464.

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

- Q: 1_Please provide postal codes for affiliations 1 and 2. Please verify that changes made in affiliations (removal of acronyms, etc.) are correct as shown.
- Q: 2_Can acronyms in affiliations 3–5 be spelled out?
- Q: 3_Please verify all author names and affiliations.
- Q: 4_Please confirm that given names and surnames are identified properly by the colors indicated. Colors will not appear in print or online, and are for proofing and coding purposes only to ensure proper indexing on PubMed.
- Q: 5_Please write out institution name for IMBICE.
- Q: 6_Please verify that four digit numbers throughout text are military time and add “hours” behind each number for military time.
- Q: 7_Is infrared as meant here instead of IR, which is used for another definition elsewhere?
- Q: 8_Please verify description of GABA as γ -aminobutyric acid, as abbreviation was only used once in paper.
- Q: 9_Are you referring to two experimental designs in sentence beginning, "The reasons for..."? If more than two, change "between" to "among."
- Q: 10_Please confirm that the financial support statement is correct and complete as set.
- Q: 11_Please verify the corresponding author's contact information. Note that if two corresponding authors are used for this article, their respective contact and/or affiliation information will appear only in the final published version and must be confirmed as accurate.
- Q: 12_This appears to be the only use of "AM" with time throughout paper. Please verify military/European times used are as meant. Can these all be made consistent with one or the other use?
- Q: 13_Please verify that 27–52 are not references.
- Q: 14_Please verify changes made to Table 1 retained your meaning.